South Korean biopharmaceutical company Celltrion Healthcare has secured European Commission (EC) marketing authorisation for the sale of Yuflyma (CT-P17) for the treatment of multiple chronic inflammatory diseases. Yuflyma
The post Celltrion Healthcare secures EC authorisation to sell Yuflyma appeared first on Pharmaceutical Business review.
This is not a CAPTIS article. Originally, it was published here.